Navigation Links
Funding boost in fight against leukaemia
Date:7/3/2008

University of Manchester researchers have been awarded 1.6 million to study a group of genes identified as playing a key role in leukaemia.

The grant, by Leukaemia Research, will fund work analysing a wide range of cancer-causing genes in the hope of targeting their common mechanisms of action for patient benefit.

"All cancers and leukaemias occur because of mutations in certain genes that stop them functioning properly," said Tony Whetton, Professor of Cancer Cell Biology and research leader.

"Mutations in a group of genes leads to unregulated activity in a group of proteins called tyrosine kinases, which change the actions of other proteins, leading to leukaemia."

The team are using state-of-the-art equipment to discover whether the different leukaemia-associated kinases contribute to the disease in the same way; if they do, it offers the opportunity to develop common therapies to block their actions.

"This would potentially be effective for many different types of leukaemia because the mutated kinase genes we are studying occur in several types of blood and bone marrow cancers," said Professor Whetton, who is Head of the School of Cancer and Imaging Sciences.

"What is also exciting is that there are already drugs that are able to block the actions of kinases. These kinase inhibitor drugs are attracting worldwide attention as a new form of treatment for certain cancers including some leukaemias. We hope to add further leukaemias to this list by understanding more fully what this range of kinases do."

Leukaemia Research currently provides more than 3.6 million in funding to the School of Cancer and Imaging Sciences, complementing ongoing research in other areas of the Manchester Cancer Research Centre (MCRC) alliance between the University and the Christie Trust.

This alliance has had a synergistic effect on cancer research in Manchester by promoting cross-disciplinary collaborations and attracting new funding from government, industry and charities.

Professor Whetton said: "In the past few years we have developed a multidisciplinary research approach, employing the latest cutting-edge technologies to take basic research towards clinical relevance as swiftly as possible.

"In so doing, we have built a research platform that not only enables leukaemia research but cancer research in general on the Christie Hospital NHS Foundation Trust site."


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. Launch of second European Cancer Research Funding survey
4. SNM applauds NAS study showing need to restore federal nuclear medicine research funding
5. Center gets national funding for child trauma research
6. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
7. Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer
8. CPF Urges Congress to Increase Funding for IPF Research in 2009 Federal Budget
9. Wild American Shrimp Board Agrees To Implement New Self-Funding Measures
10. Women Entrepreneurs Urge Veto Override of SCHIP Funding in the House
11. Coalition Urges Congress to Increase Funding for National Health Service Corps
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical companies ... to help with process innovation in drug formulation and manufacturing. CoreRx offers ... state-of-the-art analytical equipment in support of their development and manufacturing goals. , ...
(Date:4/25/2017)... Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD is ... the treatment of acute or chronic problems, I focus on preventative care with all my ... If you have any questions, always feel free to contact my office and my trained ...
(Date:4/25/2017)... ... April 25, 2017 , ... Vetoquinol USA® , a ... UCII, part of the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event ... the immunologic level. , The scientifically-developed Flexadin UCII supports the body’s normal repair ...
(Date:4/24/2017)... ... April 24, 2017 , ... Michael Vick announced his retirement ... quarterback position. The former overall number one pick in the 2001 NFL Draft, to ... holds the record for the most career rushing yards by a quarterback (6,109) and ...
(Date:4/24/2017)... ... April 24, 2017 , ... NEPC Director Kevin Welner ... Education Research Award. The award honors scholars exemplary in their capacity to communicate ... who has demonstrated the capacity to deepen the public’s understanding and appreciation of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Companion animal vaccines ... pets such as canine, avian and feline. ... such as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated ... Recombinant Vaccines. Attenuated live vaccines are derived from ... have been weakend under laboratory conditions. Conjugate vaccines ...
(Date:4/18/2017)... -- Cardinal Health (NYSE: CAH ) today is ... share (EPS) guidance and providing a preliminary view on ... this morning,s announcement of the planned acquisition of Medtronic,s ... Cardinal Health now believes that fiscal 2017 ... bottom of its previous guidance range of $5.35 to ...
(Date:4/18/2017)... SAN DIEGO , April 18, 2017  Astute ... previewed a case series to be presented at the ... , which begins today and continues through April 22. ... and IGFBP-7 , used to assess risk for acute ... acute decompensated heart failure (ADHF). Elevated ...
Breaking Medicine Technology: